Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 82K | 201K | 277K | 3M | 7M |
| Gross Profit | 58K | 149K | 213K | 2M | 5M |
| Operating Income | -2M | -2M | -2M | -3M | -1M |
| EBITDA | -2M | -151K | -2M | -3M | -508K |
| Net Income | -3M | -3M | -3M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
U.S. Stem Cell, Inc. (USRM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -59.1%, EPS growth of +32.4%, a dividend yield of 0.0%. What stands out right now is revenue -59.1%, EPS +32.4%, free cash flow +71.2% with operating margin -2096.9% and ROIC 29.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines USRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
USRM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
USRM Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for USRM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.7M
+118.1% YoY
FY Net Income
-$2.2M
+43.7% YoY
Free Cash Flow
$602.5K
+149.7% YoY
Revenue Growth
-59.1%
EPS Growth
+32.4%
Gross Margin
71.0%
Net Margin
-3483.2%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 82K | 201K | 277K | 3M | 7M |
| Gross Profit | 58K | 149K | 213K | 2M | 5M |
| Operating Income | -2M | -2M | -2M | -3M | -1M |
| EBITDA | -2M | -151K | -2M | -3M | -508K |
| Net Income | -3M | -3M | -3M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5K | 39K | 19K | 0 | 1M |
| Total Assets | 68K | 51K | 88K | 90K | 2M |
| Total Liabilities | 15M | 13M | 12M | 10M | 9M |
| Shareholder Equity | -15M | -13M | -12M | -9M | -7M |
| Total Debt | 9M | 8M | 7M | 6M | 5M |
| Net Debt | 9M | 8M | 7M | 6M | 4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
602K
+149.7% YoY
Capital Expenditures
0
Free Cash Flow
602K
+149.7% YoY
Key ratios
Gross Margin
71.0%
Operating Margin
-2096.9%
Net Margin
-3483.2%
ROE
20.8%
Debt / Equity
-0.61x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.